So it’s really important when you look at a subtype of breast cancer that has been historically understudied to have a group of physicians and a group of patient advocates work together hand in hand to highlight why they’re different and the need for separate studies and also the need for funding for those studies. So the LBCA houses all those people together...
So it’s really important when you look at a subtype of breast cancer that has been historically understudied to have a group of physicians and a group of patient advocates work together hand in hand to highlight why they’re different and the need for separate studies and also the need for funding for those studies. So the LBCA houses all those people together. It houses researchers, scientists, and patient advocates with one goal in mind, improving the outcome of lobular breast cancer patients. So because of that, we started doing a lot of philanthropic ways to raise money. Also, we talked to major organizations like ASCO, like San Antonio, and others to have grants for people who are studying lobular breast cancer, to encourage people to study it more and encourage them to apply for more grants. And I’ve been sharing the scientific side of it for the past two years, and we’ve been making great strides in that field. And just in the past three years, ASCO had zero lobular breast cancer research presented. This year, we have 10. So we are gaining momentum in that meeting. And if you look at the San Antonio Breast Cancer Symposium, for example, a few years ago, there was one or two lobular breast cancer research presentations. This past San Antonio, there were 50. So we are gaining momentum and it’s through an organization like the LBCA to showcase and put a voice for that special type of breast cancer.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
